Aethlon Medical
San Diego, California, United States · Biotechnology, Health Care, Medical
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-b
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 24
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (AEMD)
- Website
- aethlonmedical.com
- Company page
Recent activity at Aethlon Medical
- : SEC 8-K (5.02): On October 1, 2026, Aethlon Medical, Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the company’s 2020 Equity Incentive Plan. This amendment increases the number of shares of common stock authorized for issuance under the plan by 100,000 shares. The Board of Directors previously approved this amendment, contingent upon stockholder approval, on July 10, 2026. The effective date for this amendment was also set for October 1, 2026, right after stockholder approval, enhancing the company's capacity to incentivize its employees through stock options.
- : Aethlon Medical announces a definitive all-stock merger with North Immunology alongside an oversubscribed private placement targeting $180 million. The transaction is subject to shareholder and regulatory approvals.
- : Aethlon Medical merges with North Immunology
- : SEC 8-K (1.01): On September 17, 2026, Aethlon Medical, Inc. entered into a Merger Agreement with Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC, both wholly owned subsidiaries, to merge with North Immunology, Inc. This strategic move is aimed at expanding Aethlon's capabilities in the medical field, specifically in immunotherapy. The agreement details the procedures for the merger, including the conditions that must be met for the merger to proceed, although specific financial terms are not disclosed in this filing. The completion of the merger is contingent upon various conditions being satisfied or waived as outlined in the agreement.
- : SEC 8-K (5.02): On September 11, 2026, Aethlon Medical, Inc. amended the employment agreements of James B. Frakes, CEO and CFO, and Dr. Steven P. LaRosa, Chief Medical Officer. The amendments include a provision for severance payments to be paid in a lump sum rather than installments if a Change in Control occurs and the executive's employment is terminated under qualifying circumstances. This change impacts the financial arrangements for these executive officers should a transition in control happen, potentially streamlining their severance benefits during such an event.
- : SEC 8-K (8.01): Aethlon Medical, Inc. reported the exercise of certain pre-funded warrants, resulting in a total of 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. This indicates that all previously outstanding pre-funded warrants have been fully exercised. The implications of this event include an increase in the company's equity and potential dilution for existing shareholders. The filing highlights both the recent activity and the firm’s current share structure following the warrant exercises.
- : Aethlon Medical
- : SEC 8-K (5.02): On November 5, 2025, Aethlon Medical, Inc. received notification from the Nasdaq Listing Qualifications Department confirming that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. This follows a prior notification on October 16, 2025, regarding a non-compliance issue where the company's common stock had closed below the $1.00 minimum for 30 consecutive business days. Regaining compliance signifies the company's ability to continue its trading on Nasdaq, which is crucial for maintaining investor confidence and access to capital. The event demonstrates operational recovery and strategic importance for Aethlon Medical, Inc.
- : Aethlon Medical Elevates James B. Frakes to Permanent Chief Executive Officer
- : Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
Aethlon Medical funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Post-IPO Equity | $180.0M |
| Dec 2025 | Venture | $2.2M |
| Jan 2020 | Venture | $2.7M |
| Jul 2015 | Venture | $6.0M |
Leadership
- Lee Arnold, President & CEO
- GUY CIPRIANI, Director
- CHETAN SHAH, Director
- CHARLES FISHER, Director
- EDWARD BROENNIMAN, Director
- SABRINA JOHNSON, Director
- TIMOTHY RODELL, Executive Officer, Director
- Steven P. LaRosa, M.D., Chief Medical Officer
- James B. Frakes, Chief Financial Officer
- Steven P. LaRosa, Chief Medical Officer
- Steven Larosa, Chief Medical Officer
- James B. Frakes, Chief Executive Officer
Verified email and direct lines for Aethlon Medical’s decision-makers are on Fundz. See plans
Employee benefit plans
Aethlon Medical files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Aethlon Medical in the news
- Aethlon Medical, Inc. (AEMD) Company Information - Simply Wall Street (Oct 10, 2022)
- Medical Tech Stock Aethlon Medical, Inc. (Nasdaq: AEMD) Soars on Merger News - Investorideas.com (Sep 17, 2026)
- Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Lelezard (Aug 30, 2023)
- Aethlon Medical, Inc. (AEMD) stock price, news, quote and history - Yahoo Finance Singapore (May 16, 2017)
- Aethlon Medical Announces Launch of Exosome Sciences Subsidiary - PR Newswire (Sep 12, 2013)
- Aethlon Medical Announces Resignation of Inside Director to Comply with NASDAQ Corporate Governance Requirements | AEMD - Aethlon Medical, Inc. | News - OTC Markets (Feb 12, 2018)
- Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Engages Maxim Group LLC to Evaluate Strategic Opportunities - Investorideas.com (Mar 12, 2026)
- Aethlon Medical, Inc. (AEMD) stock price, news, quote and history - Yahoo Finance Australia (May 26, 2017)
Companies similar to Aethlon Medical
- Imugene · Biotechnology, Health Care, Medical, Therapeutics
- OncoNano Medicine · Biotechnology, Health Care, Medical, Therapeutics
- NuCana · Biotechnology, Health Care, Medical, Therapeutics
- NRx Pharmaceuticals · Biotechnology, Health Care, Medical, Therapeutics
- Aerska · Biotechnology, Health Care, Medical, Therapeutics
About Aethlon Medical: questions and answers
What does Aethlon Medical do?
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-b
Where is Aethlon Medical headquartered?
Aethlon Medical is headquartered in San Diego, California, United States.
How many employees does Aethlon Medical have?
Aethlon Medical has about 24 employees.
Has Aethlon Medical raised funding?
Yes. Fundz has recorded 4 funding events for Aethlon Medical. The most recent, Post-IPO Equity of $180.0M, was in Sep 2026.
Who leads Aethlon Medical?
Lee Arnold is a President & CEO at Aethlon Medical.
What is the latest news on Aethlon Medical?
On Oct 01, 2026, SEC 8-K (5.02): On October 1, 2026, Aethlon Medical, Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the company’s 2020 Equity Incentive Plan. This amendment increases the number of shares of common stock authorized for issuance under the plan by 100,000 sha
Is Aethlon Medical a public company?
Yes. Aethlon Medical is publicly traded under the ticker AEMD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy